Venetoclax, which is reported to be a selective inhibitor of Bcl-2 and which is clinically approved for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma,58 seemed to be slightly more potent in inhibiting AspH than the structurally-related navitoclax, which also inhibits other Bcl-2 family proteins (~3% versus ~10% AspH activity remaining at 20 μM). Here, ASPH is linked to B-cell chronic lymphocytic leukemia.